{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:36:11Z","timestamp":1762004171690},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>The use of the drug infliximab for the treatment of patients with Crohn's disease can be complicated by tuberculosis. A paradoxical reaction during antituberculosis chemotherapy and immunologic reconstitution after discontinuation of infliximab can result in severe disseminated tuberculosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 38-year-old Korean man with severe Crohn's disease presented with fever and diffuse abdominal pain. Infliximab had been started 2 months before admission. A chest X-ray and abdominal computed tomography scan revealed numerous miliary nodules in both lung fields and microabscesses in the spleen. Given the diagnosis of disseminated tuberculosis, the infliximab therapy was discontinued and antituberculosis therapy was promptly started. Over the next 3 months, the patient was diagnosed with tuberculosis lymphadenitis on a right supraclavicular lymph node and surgical excision of the lesion was performed. With the diagnosis of a paradoxical response, anti-tuberculous therapy was continued for 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our case suggests that patients who develop tuberculosis after infliximab exposure are at an increased risk of developing a paradoxical reaction. The current recommendation of discontinuing infliximab during tuberculosis treatment should be re-evaluated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1752-1947-3-6673","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T14:52:42Z","timestamp":1244213562000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report"],"prefix":"10.1186","volume":"3","author":[{"given":"Young Kyung","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang Wook","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ja","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Seol","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,1]]},"reference":[{"key":"603_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00063030-200216020-00005","volume":"16","author":"GM Keating","year":"2002","unstructured":"Keating GM, Perry CM: Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 2002, 16: 111-148. 10.2165\/00063030-200216020-00005.","journal-title":"BioDrugs"},{"key":"603_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","volume":"44","author":"J Keane","year":"2005","unstructured":"Keane J: TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology. 2005, 44: 714-720. 10.1093\/rheumatology\/keh567.","journal-title":"Rheumatology"},{"key":"603_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10096-003-0998-z","volume":"22","author":"VC Cheng","year":"2003","unstructured":"Cheng VC, Yam WC, Woo PC, Lau SK, Hung IF, Wong SP, Cheung WC, Yuen KY: Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003, 22: 597-602. 10.1007\/s10096-003-0998-z.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"603_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1086\/427941","volume":"40","author":"C Garcia Vidal","year":"2005","unstructured":"Garcia Vidal C, Rodr\u00edguez Fern\u00e1ndez S, Mart\u00ednez Lacasa J, Salavert M, Vidal R, Rodr\u00edguez Carballeira M, Garau J: Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005, 40: 756-759. 10.1086\/427941.","journal-title":"Clin Infect Dis"},{"key":"603_CR5","first-page":"1057","volume":"9","author":"R Belknap","year":"2005","unstructured":"Belknap R, Reves R, Burman W: Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis. 2005, 9: 1057-1058.","journal-title":"Int J Tuberc Lung Dis"},{"key":"603_CR6","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1086\/522993","volume":"45","author":"SM Arend","year":"2007","unstructured":"Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT: A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis. 2007, 45: 1470-1475. 10.1086\/522993.","journal-title":"Clin Infect Dis"},{"key":"603_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/thx.2003.019224","volume":"59","author":"RA Breen","year":"2004","unstructured":"Breen RA, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, Lipman MC: Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004, 59: 704-707. 10.1136\/thx.2003.019224.","journal-title":"Thorax"},{"key":"603_CR8","unstructured":"Treatment of tuberculosis: guidelines for national programmes. WHO. 3rd Ed. 2003."},{"key":"603_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003, 3: 148-155. 10.1016\/S1473-3099(03)00545-0.","journal-title":"Lancet Infect Dis"},{"key":"603_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001, 345: 1098-1104. 10.1056\/NEJMoa011110.","journal-title":"N Engl J Med"},{"key":"603_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1164\/ajrccm.158.1.9712001","volume":"158","author":"M Narita","year":"1998","unstructured":"Narita M, Ashkin D, Hollender ES, Pitchenik AE: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998, 158: 157-161.","journal-title":"Am J Respir Crit Care Med"},{"key":"603_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/00365540050164326","volume":"32","author":"H Bukharie","year":"2000","unstructured":"Bukharie H: Paradoxical response to anti-tuberculous drugs: resolution with corticosteroid therapy. Scand J Infect Dis. 2000, 32: 96-97. 10.1080\/00365540050164326.","journal-title":"Scand J Infect Dis"},{"key":"603_CR13","first-page":"429","volume":"153","author":"D Salmon-Ceron","year":"2002","unstructured":"Salmon-Ceron D: Recommendations for the prevention and management of tuberculosis in patients taking infliximab. Ann Med Interne (Paris). 2002, 153: 429-431.","journal-title":"Ann Med Interne (Paris)"},{"key":"603_CR14","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1086\/514993","volume":"27","author":"N Singh","year":"1998","unstructured":"Singh N, Paterson DL: Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998, 27: 1266-1277. 10.1086\/514993.","journal-title":"Clin Infect Dis"},{"key":"603_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1086\/518655","volume":"196","author":"H McIlleron","year":"2007","unstructured":"McIlleron H, Meintjes G, Burman WJ, Maartens G: Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007, 196: 63-75. 10.1086\/518655.","journal-title":"J Infect Dis"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-3-6673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-3-6673\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-3-6673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-3-6673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:06:01Z","timestamp":1630469161000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-3-6673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-3-6673","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]},"assertion":[{"value":"14 March 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"6673"}}